These insights into the role of anti-IFN-α AAbs in severe COVID-19 highlight the importance of continued research into targeted therapeutic strategies such as booster vaccination to enhance B and T cell responses which may support personalized treatment approaches for individuals at higher risk of severe disease. This evidence concerns the gene IFNA2 and COVID-19.